QL1706 plus chemo for advanced endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy for women with advanced or recurrent endometrial cancer that hasn't been treated yet. It may help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old and female
- You have stage III/IV or recurrent endometrial cancer that has not been treated with systemic therapy (like chemo or immunotherapy) and can't have surgery or radiation
- You have at least one tumor that can be measured on scans
- You are generally active and able to care for yourself (ECOG 0 or 1)
- You had a negative pregnancy test and use birth control if you could become pregnant
- You have not had other cancer treatments (like other immunotherapy, chemo, or radiation) within 4 weeks before starting this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
This trial tests a new combination of an immunotherapy drug (QL1706) plus two chemotherapy drugs (AG regimen) as a first treatment for advanced pancreatic cancer. It aims to see if this mix works better than standard care.
This trial tests if adding a new immunotherapy drug (QL1706) to standard chemotherapy works better than chemotherapy alone for triple-negative breast cancer that has returned or spread. This is for people who have already tried 1 or 2 other treatments.
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
This trial tests a combination of a new immunotherapy drug (QL1706), chemotherapy, and a targeted therapy (anlotinib) for ovarian cancer that has come back after standard platinum treatment. The goal is to see if this triple therapy can shrink tumors or slow the cancer's return.
This trial tests whether adding a new immunotherapy drug called QL1706 to standard chemotherapy before surgery can help treat early-stage cervical cancer better. The goal is to shrink tumors and improve outcomes for patients who haven't had immune therapy before.
Hear when a new Recurrent or Metastatic Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.